AdaptVac ApS: Financial statements 2018
CVR: 38732730
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 431,961 and a net result of DKK 333,539. Equity in the 2018 report amounted to DKK 63,518. The solvency ratio was 69.1%.
- Gross Profit
- DKK 431,961
- Profit/Loss
- DKK 333,539
- Equity
- DKK 63,518
- Total Assets
- DKK 91,866
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
AdaptVac ApS has published its interim report for the period June 22, 2017 – December 31, 2017.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The board consists of Morten Agertoug Nielsen (chair), Adam Frederik Sander Bertelsen, Ali El-Salanti and Jacob Hjulmand. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. According to the 2025 annual report, the company had an average of 7 employees. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity in the 2025 report amounted to DKK 10,808,696.